CHM 2.94% 1.7¢ chimeric therapeutics limited

Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib, page-5

  1. 206 Posts.
    lightbulb Created with Sketch. 47
    Does this phase 1B trial require dose / safety escalation? Or is it max strength all the way?

 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.